The present invention relates to vesicles derived from Morganella bacteria and to uses thereof. It has been experimentally confirmed by the present inventors that the vesicles were significantly reduced in clinical samples derived from patients with malignant diseases such as gastric cancer, colorectal cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, prostate cancer, and lymphoma； cardiovascular diseases such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, and strokes； diabetes, and Parkinson's disease, in comparison with a normal person and that the vesicles inhibited carcinogenesis in cancer animal models while inhibiting the secretion of inflammatory mediators caused by pathogenic vesicles. The vesicles derived from Morganella bacteria according to the present invention will be usefully employed for the purposes of developing a method for diagnosing malignant diseases such as gastric cancer, colorectal cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, prostate cancer, and lymphoma； cardiovascular diseases such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, and strokes； diabetes, and Parkinson's disease, and a composition for preventing or treating said diseases or inflammatory diseases.La présente invention concerne des vésicules issues de bactéries Morganella et des utilisations associées. Il a été confirmé expérimentalement par les présents inventeurs que la proportion des vésicules a été significativement réduite dans des échantillons cliniques provenant de patients atteints de maladies malignes telles que le cancer gastrique, le cancer colorectal, le cancer du pancréas, le cholangiocarcinome, le cancer du sein, le cancer de l'ovaire, le cancer de la vessie, le cancer de la prostate et le lymphome ； de maladies cardiovasculaires telles que l'infarctus du myocarde, la cardiomyopathie, la fibrillation auriculaire
